http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 18 Aug 2026 17:30:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++S-4++++++++NextCure%2C+Inc.+++++++++++++++++++++++/26945589.html <p><a target="_blank" href="http://archive.fast-edgar.com/20260818/A8B2M22C8Z22B9ZZ2HZD2ZZZIKGQR2R2Z28Q">http://archive.fast-edgar.com/20260818/A8B2M22C8Z22B9ZZ2HZD2ZZZIKGQR2R2Z28Q</a></p> <p> Filed on: August 18, 2026 </p> http://www.streetinsider.com/SEC+Filings/Form++S-4++++++++NextCure%2C+Inc.+++++++++++++++++++++++/26945589.html Tue, 18 Aug 2026 17:30:00 -0400 NXTC O.26593406 http://www.streetinsider.com/SEC+Filings/Form++S-4++++++++NextCure%2C+Inc.+++++++++++++++++++++++/26945589.html <p><a target="_blank" href="http://archive.fast-edgar.com/20260818/A8B2M22C8Z22B9ZZ2HZD2ZZZIKGQR2R2Z28Q">http://archive.fast-edgar.com/20260818/A8B2M22C8Z22B9ZZ2HZD2ZZZIKGQR2R2Z28Q</a></p> <p> Filed on: August 18, 2026 </p> http://www.streetinsider.com/SEC+Filings/Form++S-4++++++++NextCure%2C+Inc.+++++++++++++++++++++++/26945589.html Tue, 18 Aug 2026 17:30:00 -0400 NXTC O.26593406 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++NextCure%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+ADAR1+Capital+Management%2C+LLC/26933330.html si-local-file:///var/storage/secattach/20260814/26933330.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++NextCure%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+ADAR1+Capital+Management%2C+LLC/26933330.html Fri, 14 Aug 2026 21:33:00 -0400 NXTC O.26593406 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++NextCure%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+ADAR1+Capital+Management%2C+LLC/26933330.html si-local-file:///var/storage/secattach/20260814/26933330.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++NextCure%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+ADAR1+Capital+Management%2C+LLC/26933330.html Fri, 14 Aug 2026 21:33:00 -0400 NXTC O.26593406 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++NextCure%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+Ikarian+Capital%2C+LLC/26933291.html si-local-file:///var/storage/secattach/20260814/26933291.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++NextCure%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+Ikarian+Capital%2C+LLC/26933291.html Fri, 14 Aug 2026 20:58:00 -0400 NXTC O.26593406 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++NextCure%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+Ikarian+Capital%2C+LLC/26933291.html si-local-file:///var/storage/secattach/20260814/26933291.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++NextCure%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+Ikarian+Capital%2C+LLC/26933291.html Fri, 14 Aug 2026 20:58:00 -0400 NXTC O.26593406 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++NextCure%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+Squadron+Capital+Management+LLC/26928229.html si-local-file:///var/storage/secattach/20260814/26928229.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++NextCure%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+Squadron+Capital+Management+LLC/26928229.html Fri, 14 Aug 2026 13:10:00 -0400 NXTC O.26593406 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++NextCure%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+Squadron+Capital+Management+LLC/26928229.html si-local-file:///var/storage/secattach/20260814/26928229.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++NextCure%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+Squadron+Capital+Management+LLC/26928229.html Fri, 14 Aug 2026 13:10:00 -0400 NXTC O.26593406 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++NextCure%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+Affinity+Asset+Advisors%2C+LLC/26920754.html si-local-file:///var/storage/secattach/20260813/26920754.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++NextCure%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+Affinity+Asset+Advisors%2C+LLC/26920754.html Thu, 13 Aug 2026 16:05:00 -0400 NXTC O.26593406 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++NextCure%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+Affinity+Asset+Advisors%2C+LLC/26920754.html si-local-file:///var/storage/secattach/20260813/26920754.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++NextCure%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+Affinity+Asset+Advisors%2C+LLC/26920754.html Thu, 13 Aug 2026 16:05:00 -0400 NXTC O.26593406 http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+NextCure+Inc.+%28NXTC%29/26916140.html <p>H.C. Wainwright analyst Emily Bodnar reiterated a Buy rating and $20.00 price target on NextCure Inc. (NASDAQ: NXTC).</p><p>The analyst commented: "As a reminder, NextCure and Avere Therapeutics have announced a reverse merger, with the combined company to operate as Avere Therapeutics and trade under Nasdaq with ticker symbol "AVRX". The transaction is on track to complete in 2H26 subject to stockholder approval and other customary closing conditions. As part of the merger, Avere also announced a $320M private placement led by Fairmount and Hansoh with participation from large investment firms including Janus Henderson Investors and Wellington Management. The financing includes http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+NextCure+Inc.+%28NXTC%29/26916140.html Thu, 13 Aug 2026 06:59:12 -0400 NXTC http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++NextCure%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+Adage+Capital+Management%2C+L.P./26911254.html si-local-file:///var/storage/secattach/20260812/26911254.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++NextCure%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+Adage+Capital+Management%2C+L.P./26911254.html Wed, 12 Aug 2026 12:07:00 -0400 NXTC O.26593406 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++NextCure%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+Adage+Capital+Management%2C+L.P./26911254.html si-local-file:///var/storage/secattach/20260812/26911254.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++NextCure%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+Adage+Capital+Management%2C+L.P./26911254.html Wed, 12 Aug 2026 12:07:00 -0400 NXTC O.26593406 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NextCure%2C+Inc.++++++++++++For%3A+Aug+10++Filed+by%3A+Simcere+Pharmaceutical+Group+Ltd/26911064.html si-local-file:///var/storage/secattach/20260812/26911064.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NextCure%2C+Inc.++++++++++++For%3A+Aug+10++Filed+by%3A+Simcere+Pharmaceutical+Group+Ltd/26911064.html Wed, 12 Aug 2026 11:35:00 -0400 NXTC O.26593406 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NextCure%2C+Inc.++++++++++++For%3A+Aug+10++Filed+by%3A+Simcere+Pharmaceutical+Group+Ltd/26911064.html si-local-file:///var/storage/secattach/20260812/26911064.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NextCure%2C+Inc.++++++++++++For%3A+Aug+10++Filed+by%3A+Simcere+Pharmaceutical+Group+Ltd/26911064.html Wed, 12 Aug 2026 11:35:00 -0400 NXTC O.26593406 http://www.streetinsider.com/SEC+Filings/Form++425++++++++NextCure%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+NextCure%2C+Inc./26897600.html si-local-file:///var/storage/secattach/20260810/26897600.html http://www.streetinsider.com/SEC+Filings/Form++425++++++++NextCure%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+NextCure%2C+Inc./26897600.html Mon, 10 Aug 2026 16:02:00 -0400 NXTC O.26593406 http://www.streetinsider.com/SEC+Filings/Form++425++++++++NextCure%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+NextCure%2C+Inc./26897600.html si-local-file:///var/storage/secattach/20260810/26897600.html http://www.streetinsider.com/SEC+Filings/Form++425++++++++NextCure%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+NextCure%2C+Inc./26897600.html Mon, 10 Aug 2026 16:02:00 -0400 NXTC O.26593406 http://www.streetinsider.com/Equity+Offerings/Avere+Therapeutics+raises+%24500M+in+private+placement+for+drug+program/26894105.html <p>Avere Therapeutics, Inc., a privately held biotechnology company, has announced a $500 million private placement from a syndicate of institutional healthcare investors to support the development of AVR-001, a once-weekly oral IL-23 receptor antagonist.</p> <p>The placement consists of common stock and pre-funded warrants. Participants include Venrock Healthcare Capital Partners, General Atlantic, Blackstone Multi-Asset Investing, RTW Investments, Eventide Asset Management, BB Biotech, Sirenia Capital Management LP, ADAR1 Capital Management, Wellington Management, Janus Henderson Investors, and other institutional investors.</p> <p>The $500 million raise comes in addition to a previously announced $320 million concurrent private placement. Combined, the two financings are expected to fully fund http://www.streetinsider.com/Equity+Offerings/Avere+Therapeutics+raises+%24500M+in+private+placement+for+drug+program/26894105.html Mon, 10 Aug 2026 07:01:11 -0400 A.07414818 A.12626223 A.12939998 A.50100012 A.50200171 A.50214655 A.50216428 A.60001732 AVRX NXTC O.00163824 O.00478238 O.00812673 O.03227691 O.07579093 O.10869727 O.20113046 O.26593406 O.55864350 http://www.streetinsider.com/Equity+Offerings/Avere+Therapeutics+raises+%24500M+in+private+placement+for+drug+program/26894105.html <p>Avere Therapeutics, Inc., a privately held biotechnology company, has announced a $500 million private placement from a syndicate of institutional healthcare investors to support the development of AVR-001, a once-weekly oral IL-23 receptor antagonist.</p> <p>The placement consists of common stock and pre-funded warrants. Participants include Venrock Healthcare Capital Partners, General Atlantic, Blackstone Multi-Asset Investing, RTW Investments, Eventide Asset Management, BB Biotech, Sirenia Capital Management LP, ADAR1 Capital Management, Wellington Management, Janus Henderson Investors, and other institutional investors.</p> <p>The $500 million raise comes in addition to a previously announced $320 million concurrent private placement. Combined, the two financings are expected to fully fund http://www.streetinsider.com/Equity+Offerings/Avere+Therapeutics+raises+%24500M+in+private+placement+for+drug+program/26894105.html Mon, 10 Aug 2026 07:01:11 -0400 A.07414818 A.12626223 A.12939998 A.50100012 A.50200171 A.50214655 A.50216428 A.60001732 AVRX NXTC O.00163824 O.00478238 O.00812673 O.03227691 O.07579093 O.10869727 O.20113046 O.26593406 O.55864350 http://www.streetinsider.com/Equity+Offerings/Avere+Therapeutics+raises+%24500M+in+private+placement+for+drug+program/26894105.html <p>Avere Therapeutics, Inc., a privately held biotechnology company, has announced a $500 million private placement from a syndicate of institutional healthcare investors to support the development of AVR-001, a once-weekly oral IL-23 receptor antagonist.</p> <p>The placement consists of common stock and pre-funded warrants. Participants include Venrock Healthcare Capital Partners, General Atlantic, Blackstone Multi-Asset Investing, RTW Investments, Eventide Asset Management, BB Biotech, Sirenia Capital Management LP, ADAR1 Capital Management, Wellington Management, Janus Henderson Investors, and other institutional investors.</p> <p>The $500 million raise comes in addition to a previously announced $320 million concurrent private placement. Combined, the two financings are expected to fully fund http://www.streetinsider.com/Equity+Offerings/Avere+Therapeutics+raises+%24500M+in+private+placement+for+drug+program/26894105.html Mon, 10 Aug 2026 07:01:11 -0400 A.07414818 A.12626223 A.12939998 A.50100012 A.50200171 A.50214655 A.50216428 A.60001732 AVRX NXTC O.00163824 O.00478238 O.00812673 O.03227691 O.07579093 O.10869727 O.20113046 O.26593406 O.55864350 http://www.streetinsider.com/Equity+Offerings/Avere+Therapeutics+raises+%24500M+in+private+placement+for+drug+program/26894105.html <p>Avere Therapeutics, Inc., a privately held biotechnology company, has announced a $500 million private placement from a syndicate of institutional healthcare investors to support the development of AVR-001, a once-weekly oral IL-23 receptor antagonist.</p> <p>The placement consists of common stock and pre-funded warrants. Participants include Venrock Healthcare Capital Partners, General Atlantic, Blackstone Multi-Asset Investing, RTW Investments, Eventide Asset Management, BB Biotech, Sirenia Capital Management LP, ADAR1 Capital Management, Wellington Management, Janus Henderson Investors, and other institutional investors.</p> <p>The $500 million raise comes in addition to a previously announced $320 million concurrent private placement. Combined, the two financings are expected to fully fund http://www.streetinsider.com/Equity+Offerings/Avere+Therapeutics+raises+%24500M+in+private+placement+for+drug+program/26894105.html Mon, 10 Aug 2026 07:01:11 -0400 A.07414818 A.12626223 A.12939998 A.50100012 A.50200171 A.50214655 A.50216428 A.60001732 AVRX NXTC O.00163824 O.00478238 O.00812673 O.03227691 O.07579093 O.10869727 O.20113046 O.26593406 O.55864350 http://www.streetinsider.com/Equity+Offerings/Avere+Therapeutics+raises+%24500M+in+private+placement+for+drug+program/26894105.html <p>Avere Therapeutics, Inc., a privately held biotechnology company, has announced a $500 million private placement from a syndicate of institutional healthcare investors to support the development of AVR-001, a once-weekly oral IL-23 receptor antagonist.</p> <p>The placement consists of common stock and pre-funded warrants. Participants include Venrock Healthcare Capital Partners, General Atlantic, Blackstone Multi-Asset Investing, RTW Investments, Eventide Asset Management, BB Biotech, Sirenia Capital Management LP, ADAR1 Capital Management, Wellington Management, Janus Henderson Investors, and other institutional investors.</p> <p>The $500 million raise comes in addition to a previously announced $320 million concurrent private placement. Combined, the two financings are expected to fully fund http://www.streetinsider.com/Equity+Offerings/Avere+Therapeutics+raises+%24500M+in+private+placement+for+drug+program/26894105.html Mon, 10 Aug 2026 07:01:11 -0400 A.07414818 A.12626223 A.12939998 A.50100012 A.50200171 A.50214655 A.50216428 A.60001732 AVRX NXTC O.00163824 O.00478238 O.00812673 O.03227691 O.07579093 O.10869727 O.20113046 O.26593406 O.55864350 http://www.streetinsider.com/Equity+Offerings/Avere+Therapeutics+raises+%24500M+in+private+placement+for+drug+program/26894105.html <p>Avere Therapeutics, Inc., a privately held biotechnology company, has announced a $500 million private placement from a syndicate of institutional healthcare investors to support the development of AVR-001, a once-weekly oral IL-23 receptor antagonist.</p> <p>The placement consists of common stock and pre-funded warrants. Participants include Venrock Healthcare Capital Partners, General Atlantic, Blackstone Multi-Asset Investing, RTW Investments, Eventide Asset Management, BB Biotech, Sirenia Capital Management LP, ADAR1 Capital Management, Wellington Management, Janus Henderson Investors, and other institutional investors.</p> <p>The $500 million raise comes in addition to a previously announced $320 million concurrent private placement. Combined, the two financings are expected to fully fund http://www.streetinsider.com/Equity+Offerings/Avere+Therapeutics+raises+%24500M+in+private+placement+for+drug+program/26894105.html Mon, 10 Aug 2026 07:01:11 -0400 A.07414818 A.12626223 A.12939998 A.50100012 A.50200171 A.50214655 A.50216428 A.60001732 AVRX NXTC O.00163824 O.00478238 O.00812673 O.03227691 O.07579093 O.10869727 O.20113046 O.26593406 O.55864350 http://www.streetinsider.com/Equity+Offerings/Avere+Therapeutics+raises+%24500M+in+private+placement+for+drug+program/26894105.html <p>Avere Therapeutics, Inc., a privately held biotechnology company, has announced a $500 million private placement from a syndicate of institutional healthcare investors to support the development of AVR-001, a once-weekly oral IL-23 receptor antagonist.</p> <p>The placement consists of common stock and pre-funded warrants. Participants include Venrock Healthcare Capital Partners, General Atlantic, Blackstone Multi-Asset Investing, RTW Investments, Eventide Asset Management, BB Biotech, Sirenia Capital Management LP, ADAR1 Capital Management, Wellington Management, Janus Henderson Investors, and other institutional investors.</p> <p>The $500 million raise comes in addition to a previously announced $320 million concurrent private placement. Combined, the two financings are expected to fully fund http://www.streetinsider.com/Equity+Offerings/Avere+Therapeutics+raises+%24500M+in+private+placement+for+drug+program/26894105.html Mon, 10 Aug 2026 07:01:11 -0400 A.07414818 A.12626223 A.12939998 A.50100012 A.50200171 A.50214655 A.50216428 A.60001732 AVRX NXTC O.00163824 O.00478238 O.00812673 O.03227691 O.07579093 O.10869727 O.20113046 O.26593406 O.55864350 http://www.streetinsider.com/Equity+Offerings/Avere+Therapeutics+raises+%24500M+in+private+placement+for+drug+program/26894105.html <p>Avere Therapeutics, Inc., a privately held biotechnology company, has announced a $500 million private placement from a syndicate of institutional healthcare investors to support the development of AVR-001, a once-weekly oral IL-23 receptor antagonist.</p> <p>The placement consists of common stock and pre-funded warrants. Participants include Venrock Healthcare Capital Partners, General Atlantic, Blackstone Multi-Asset Investing, RTW Investments, Eventide Asset Management, BB Biotech, Sirenia Capital Management LP, ADAR1 Capital Management, Wellington Management, Janus Henderson Investors, and other institutional investors.</p> <p>The $500 million raise comes in addition to a previously announced $320 million concurrent private placement. Combined, the two financings are expected to fully fund http://www.streetinsider.com/Equity+Offerings/Avere+Therapeutics+raises+%24500M+in+private+placement+for+drug+program/26894105.html Mon, 10 Aug 2026 07:01:11 -0400 A.07414818 A.12626223 A.12939998 A.50100012 A.50200171 A.50214655 A.50216428 A.60001732 AVRX NXTC O.00163824 O.00478238 O.00812673 O.03227691 O.07579093 O.10869727 O.20113046 O.26593406 O.55864350